GunjanLalitchandraShahMDMS

PubMed

• Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...
  Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
  Journal of Clinical Oncology. 2025-02-10
• Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
  Daniel J Landsburg, Matthew J Frigault, Michael Heim, Stephen Ronan Foley, Brian Hill
  Journal for Immunotherapy of Cancer. 2025-02-09
• CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in.
  Karlo Perica, Nayan Jain, Michael Scordo, Ruchi Patel, Ozgur Can Eren
  The New England Journal of Medicine. 2025-02-06

Abstracts/Posters

• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) ...
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Gunjan Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Gunjan Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilizati...
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation
  Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Gunjan Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplan... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all